Figure 5.
Cytokine analysis. (A) Trends in cytokine levels compared between arms AC (blue circles) vs TMS (red circles) at 3, 6, 9, and 12 months after HSCT. (B) Trend and differences between ST2 levels after HSCT among patients who did (orange circles) or did not (gray circles) develop grade 2 to 4 aGVHD; and did (purple circles) or did not (gray circles) develop moderate-to-severe cGVHD. (C) Trend and differences between CXCL10 levels after HSCT among patients who did (orange circles) or did not (gray circles) develop grade 2 to 4 aGVHD; and did (purple circles) or did not (gray circles) develop moderate-to-severe cGVHD. (D) Higher levels of TNF-α and IL-6 at 6 months were associated with worse OS. TNF-α median, 2.7 pg/mL; IL-6 quartiles: Q1 <0.84 pg/mL; Q2 0.84 to 1.3 pg/mL; Q3 >1.3 to 2.2 pg/mL; Q4 >2.2 pg/mL. # indicates P value <.05; q value > 0.05.

Cytokine analysis. (A) Trends in cytokine levels compared between arms AC (blue circles) vs TMS (red circles) at 3, 6, 9, and 12 months after HSCT. (B) Trend and differences between ST2 levels after HSCT among patients who did (orange circles) or did not (gray circles) develop grade 2 to 4 aGVHD; and did (purple circles) or did not (gray circles) develop moderate-to-severe cGVHD. (C) Trend and differences between CXCL10 levels after HSCT among patients who did (orange circles) or did not (gray circles) develop grade 2 to 4 aGVHD; and did (purple circles) or did not (gray circles) develop moderate-to-severe cGVHD. (D) Higher levels of TNF-α and IL-6 at 6 months were associated with worse OS. TNF-α median, 2.7 pg/mL; IL-6 quartiles: Q1 <0.84 pg/mL; Q2 0.84 to 1.3 pg/mL; Q3 >1.3 to 2.2 pg/mL; Q4 >2.2 pg/mL. # indicates P value <.05; q value > 0.05.

Close Modal

or Create an Account

Close Modal
Close Modal